FDA Alert
FDA Alert
03/04/2024
Anthony Calabro, MA
The FDA approved irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin as a first-line regimen for the management of patients with metastatic pancreatic adenocarcinoma.
03/04/2024
FDA ALERT
FDA ALERT
01/26/2024
Anthony Calabro, MA
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
01/26/2024
fda alert
fda alert
10/19/2023
Leigh Precopio
The FDA approved the use of quizartinib for certain patient populations with acute myeloid leukemia in July 2023.
10/19/2023
FDA Alert
FDA Alert
09/11/2023
Anthony Calabro, MA
The FDA approval follows a single-arm, multicenter, open-label trial in 91 patients with uveal melanoma with unresectable hepatic metastases.
09/11/2023
Bladder Cancer
Bladder Cancer
01/04/2023
The FDA’s approval of the first gene therapy to treat high-risk non-muscle-invasive bladder cancer follow a multicenter clinical trial.
01/04/2023
Oncology
Oncology
09/25/2017
The US Food and Drug Administration (FDA) has indicated nivolumab for intravenous use in patients with previously treated liver cancer.
09/25/2017
Oncology
Oncology
09/25/2017
The US Food and Drug Administration (FDA) expanded the approval of a targeted therapy to treat gastric or gastroesophageal junction (GEJ) cancer.
09/25/2017
Breast cancer
Breast cancer
08/28/2017
The US Food and Drug Administration has expanded the approval of Faslodex, a hormonal therapy for the treatment of breast cancer first approved in 2002.
08/28/2017
Leukemia
Leukemia
08/17/2017
The US Food and Drug Administration has approved a new option for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
08/17/2017
Hematology
Hematology
08/02/2017
After results from a recent trial demonstrated its efficacy, the FDA expanded the indication of a cancer drug to include adult patients with chronic graft versus host disease who do not respond to other...
08/02/2017